Xeris Biopharma Holdings, Inc.XERS stock score: 64/100

$16.62 · -2.18% · Scored Nov 19, 2026

Technical
68
Fundamental
63
News
—

The reading

Xeris Biopharma (XERS) scores 64 out of 100, which reads neutral, higher than 87% of Healthcare stocks and 89% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 63, technicals 68.

Among the fundamentals, Earnings Growth (Annual) at 100 and Revenue Growth (5-Year) at 99 score highest, while Price to Book Ratio at 0 weighs the most against it.

On the daily chart, trend-following indicators average 75 and contrarian oscillators 22 — a split worth reading before trusting the technical total.

Since Aug 23, 2026 the composite has ranged from 56 to 66, and it ends the period where it started.

About Xeris Biopharma

Xeris Biopharma Holdings (XERS) is a biopharmaceutical company that develops and sells medicines for endocrine and other specialty conditions. Its main growth product is Recorlev, a treatment for endogenous hypercortisolemia in adults with Cushing’s syndrome, a rare condition in which the body produces too much cortisol. Xeris also sells Gvoke, a ready-to-use liquid glucagon for severe low blood sugar in people with diabetes, offered in an autoinjector, prefilled syringe and other forms, and Keveyis, a treatment for primary periodic paralysis. The company uses its XeriSol and XeriJect formulation technologies to create stable, ready-to-use injectable versions of drugs, and it licenses these technologies to other drugmakers. Its pipeline includes a once-weekly injectable form of levothyroxine for hypothyroidism. Xeris sells its products mainly in the United States through specialty pharmacies and distributors, and it earns money mainly from product sales, with some revenue from licensing and partnerships.

Recorlev competes with Recordati’s Isturisa and Corcept Therapeutics’ Korlym, while Gvoke competes with Amphastar’s Baqsimi and generic glucagon kits. Xeris’s edge rests on its formulation technology, a specialized endocrinology sales force and its focus on rare and underserved conditions. Investors who follow XERS stock tend to watch Recorlev sales and the number of patients on therapy. Gvoke prescriptions and insurance coverage are closely followed. Progress of its weekly levothyroxine program, profitability and debt levels are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward XERS’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

63

Pulling it up

Holding it back

  • Price-to-Book ratio compares market value to book value.

  • Debt-to-Equity ratio measures financial leverage by comparing total debt to shareholder equity.

  • Trailing P/E ratio uses the last 12 months of actual earnings.

38 weighted scorers; 1 had no data today and are left out rather than counted as zero.

Technical · daily

68

Pulling it up

  • Rate of Change measures the percentage change in price over a specified period.

  • Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.

  • VWAP100

    Volume Weighted Average Price (VWAP) shows the average price weighted by volume.

Holding it back

  • Relative Strength Index (14-period) measures momentum by comparing recent gains to losses.

  • Money Flow Index (14-period) is a volume-weighted RSI that identifies overbought and oversold conditions.

  • Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.

62 weighted scorers; 3 had no data today and are left out rather than counted as zero.

Technical score by timeframe

ChartScoreWeight
Hourly481
Daily683
Weekly722
Monthly752

Composite score, last 90 days

05010064Aug 23, 2026Nov 19, 2026Aug 23, 2026: 64Aug 24, 2026: 64Aug 25, 2026: 63Aug 26, 2026: 64Aug 27, 2026: 63Aug 28, 2026: 62Aug 29, 2026: 62Aug 30, 2026: 62Aug 31, 2026: 62Sep 1, 2026: 61Sep 2, 2026: 62Sep 4, 2026: 62Sep 5, 2026: 61Sep 6, 2026: 61Sep 7, 2026: 61Sep 8, 2026: 62Sep 9, 2026: 57Sep 10, 2026: 56Sep 11, 2026: 56Sep 12, 2026: 57Sep 13, 2026: 57Sep 14, 2026: 57Sep 15, 2026: 57Sep 16, 2026: 58Sep 17, 2026: 60Sep 18, 2026: 60Sep 19, 2026: 60Sep 20, 2026: 60Sep 21, 2026: 63Sep 22, 2026: 63Sep 23, 2026: 63Sep 24, 2026: 63Sep 25, 2026: 63Sep 26, 2026: 63Sep 27, 2026: 63Sep 28, 2026: 63Sep 29, 2026: 63Sep 30, 2026: 62Oct 1, 2026: 61Oct 2, 2026: 61Oct 3, 2026: 61Oct 4, 2026: 61Oct 5, 2026: 63Oct 6, 2026: 63Oct 7, 2026: 62Oct 8, 2026: 62Oct 9, 2026: 63Oct 10, 2026: 63Oct 11, 2026: 63Oct 12, 2026: 63Oct 13, 2026: 62Oct 14, 2026: 60Oct 15, 2026: 61Oct 16, 2026: 61Oct 17, 2026: 61Oct 18, 2026: 61Oct 19, 2026: 62Oct 20, 2026: 63Oct 21, 2026: 62Oct 22, 2026: 61Oct 23, 2026: 59Oct 24, 2026: 59Oct 25, 2026: 59Oct 26, 2026: 59Oct 27, 2026: 61Oct 28, 2026: 61Oct 29, 2026: 61Oct 30, 2026: 61Nov 1, 2026: 61Nov 2, 2026: 59Nov 3, 2026: 59Nov 4, 2026: 60Nov 5, 2026: 62Nov 6, 2026: 62Nov 7, 2026: 64Nov 10, 2026: 63Nov 11, 2026: 64Nov 12, 2026: 66Nov 13, 2026: 65Nov 14, 2026: 65Nov 15, 2026: 65Nov 16, 2026: 64Nov 17, 2026: 64Nov 18, 2026: 64Nov 19, 2026: 64
Show the daily numbers
DateComposite
Nov 19, 202664
Nov 18, 202664
Nov 17, 202664
Nov 16, 202664
Nov 15, 202665
Nov 14, 202665
Nov 13, 202665
Nov 12, 202666
Nov 11, 202664
Nov 10, 202663
Nov 7, 202664
Nov 6, 202662
Nov 5, 202662
Nov 4, 202660
Nov 3, 202659
Nov 2, 202659
Nov 1, 202661
Oct 30, 202661
Oct 29, 202661
Oct 28, 202661
Oct 27, 202661
Oct 26, 202659
Oct 25, 202659
Oct 24, 202659
Oct 23, 202659
Oct 22, 202661
Oct 21, 202662
Oct 20, 202663
Oct 19, 202662
Oct 18, 202661
Oct 17, 202661
Oct 16, 202661
Oct 15, 202661
Oct 14, 202660
Oct 13, 202662
Oct 12, 202663
Oct 11, 202663
Oct 10, 202663
Oct 9, 202663
Oct 8, 202662
Oct 7, 202662
Oct 6, 202663
Oct 5, 202663
Oct 4, 202661
Oct 3, 202661
Oct 2, 202661
Oct 1, 202661
Sep 30, 202662
Sep 29, 202663
Sep 28, 202663
Sep 27, 202663
Sep 26, 202663
Sep 25, 202663
Sep 24, 202663
Sep 23, 202663
Sep 22, 202663
Sep 21, 202663
Sep 20, 202660
Sep 19, 202660
Sep 18, 202660
Sep 17, 202660
Sep 16, 202658
Sep 15, 202657
Sep 14, 202657
Sep 13, 202657
Sep 12, 202657
Sep 11, 202656
Sep 10, 202656
Sep 9, 202657
Sep 8, 202662
Sep 7, 202661
Sep 6, 202661
Sep 5, 202661
Sep 4, 202662
Sep 2, 202662
Sep 1, 202661
Aug 31, 202662
Aug 30, 202662
Aug 29, 202662
Aug 28, 202662
Aug 27, 202663
Aug 26, 202664
Aug 25, 202663
Aug 24, 202664
Aug 23, 202664

Key facts

Market cap
$3.0B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.84
Risk grade (1–10)
8
Next earnings
Nov 5, 2026

Questions

What is XERS's stock rating today?

XERS scores 64/100 (Neutral) as of Nov 19, 2026: technical 68, fundamental 63. Scores are recomputed every night.

What does Xeris Biopharma do?

Xeris Biopharma Holdings (XERS) is a biopharmaceutical company that develops and sells medicines for endocrine and other specialty conditions. Its main growth product is Recorlev, a treatment for endogenous hypercortisolemia in adults with Cushing’s syndrome, a rare condition in which the body produces too much cortisol.

Is XERS stock a buy?

The score is not a buy or sell recommendation. A 64 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the XERS score calculated?

100 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

XERS stock score

HTML

<a href="https://stocksscores.com/stocks/xers/"><img src="https://stocksscores.com/stocks/xers/badge.svg" alt="XERS stock score" height="20"></a>

Markdown

[![XERS stock score](https://stocksscores.com/stocks/xers/badge.svg)](https://stocksscores.com/stocks/xers/)